Skip to main content
    Z

    Zura Bio Limited Class A Ordinary Shares (ZURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.08
    -0.16 (-12.90%)

    Market Cap: $119.44M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zura Bio Limited Class A Ordinary Shares (ZURA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Zura Bio Limited Class A Ordinary Shares are TuHURA Biosciences (HURA), LENZ Therapeutics (LENZ) and Rallybio (RLYB). By market cap, Zura Bio Limited Class A Ordinary Shares ranks 7th of the 13 companies on this page; Zentalis Pharmaceuticals Llc (ZNTL) is the largest at $167.05M.

    Peer Comparison

    ZURA's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Zura Bio Limited Class A Ordinary Shares (ZURA)$119.44MN/AN/A0.0%N/A0.0%0.00%
    TuHURA Biosciences Inc (HURA)$88.58MN/AN/A0.0%-81.8%0.0%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Rallybio Corp (RLYB)$88.03MN/A203.1x6177.0%N/A0.0%0.00%
    Zentalis Pharmaceuticals Llc (ZNTL)$167.05MN/AN/A0.0%N/A0.0%0.00%
    Unicycive Therapeutics Inc (UNCY)$97.25MN/AN/A0.0%N/A0.0%0.00%
    Tiziana Life Sciences Ltd (TLSA)$72.53MN/AN/A0.0%N/A0.0%0.00%
    Kazia Therapeutics Ltd ADR (KZIA)$75.65MN/AN/A0.0%N/A312.4%0.00%
    Sutro Biopharma (STRO)$163.03MN/A3.4x0.0%N/A-6.1%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Sionna Therapeutics, Inc. Common Stock (SION)$150.63MN/AN/A0.0%N/A0.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    OnKure Therapeutics, Inc. (OKUR)$108.33MN/AN/A0.0%N/A0.0%0.00%
    Peer median$119.05MN/A25.4x0.0%-81.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Zura Bio Limited Class A Ordinary Shares, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    TuHURA Biosciences Inc (HURA)
    TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases.
    HURA competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    Rallybio Corp (RLYB)
    Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases...
    RLYB competitors
    Zentalis Pharmaceuticals Llc (ZNTL)
    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment...
    ZNTL competitors
    Unicycive Therapeutics Inc (UNCY)
    Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases...
    UNCY competitors
    Tiziana Life Sciences Ltd (TLSA)
    Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat...
    Kazia Therapeutics Ltd ADR (KZIA)
    Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
    Sutro Biopharma (STRO)
    Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company.
    STRO competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors
    Sionna Therapeutics, Inc. Common Stock (SION)
    Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders...
    SION competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    OnKure Therapeutics, Inc. (OKUR)
    OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
    OKUR competitors

    Frequently Asked Questions About ZURA

    Who are Zura Bio Limited Class A Ordinary Shares' main competitors?

    The companies most similar to Zura Bio Limited Class A Ordinary Shares include TuHURA Biosciences (HURA), LENZ Therapeutics (LENZ), Rallybio (RLYB), Zentalis Pharmaceuticals Llc (ZNTL) and Unicycive Therapeutics (UNCY), listed from the closest match.

    Who is Zura Bio Limited Class A Ordinary Shares' biggest competitor?

    Zentalis Pharmaceuticals Llc (ZNTL) is the largest of the similar companies at $167.05M; TuHURA Biosciences (HURA) is the closest match by business profile, size, sector and industry.

    How does ZURA stock compare with its competitors?

    ZURA's net margin is 0.0% against a peer median of 0.0%.

    Which of Zura Bio Limited Class A Ordinary Shares' competitors pays a higher dividend?

    Zura Bio Limited Class A Ordinary Shares pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Zura Bio Limited Class A Ordinary Shares bigger than its competitors?

    No. Zura Bio Limited Class A Ordinary Shares is 7th by market cap among the 13 companies on this page; the largest is Zentalis Pharmaceuticals Llc (ZNTL) at $167.05M.